Market started well like yesterday but succumbed to afternoon profit taking , and Opportunity Stocks were mixed in the end.
OEC hit a positive note earlier in the day reaching 39c before someone sold $100 worth of shares at 33c to take it down 8.3%! [seriously, such trading action is rather insensitive to holders ] - may be a case of someone queuing below wanting to bring the price back down or someone selling remnant shares at whatever price he/she could get without care for anything else.
NXS was the other detractor down 6.6% today and looking very oversold.
On a positive note, ISX hit a new high of 82.5c before closing at 80c up 14.3% on its net cashflow positive result for the quarter and its ADI licence application approval going well. For a while since it was put on, returns were negative but after two months, gains are now at 24%.
VHT also produced good results in accordance with guidance and as I had expected, the rebound happened with a 6.1% gain on the day [last week I indicated it was good time to bottom fish this in anticipation of results].
The other gainer was EVS, this one has been a laggard but today went to 14.5c before closing at 14c for a gain of 7.7% - I am hopeful it can turnaround the present 17% deficit with a good set of results but may have to wait until next month.
And good to see ANO back above $5 which I expected anyway -its annual report due next week I believe and a positive result should see this get back up above $6.
Finally TNY is undertaking a CR, but this should not be seen as a concern, after all TNY is just a $35m company and its share base is not extended (just 33m shares!!) and it needs the cash to help grow its franchise which is doing great in the US. Selling down on day of release of its CR news to buy back at a lower price is something traders do - but sometimes you get wrong footed as did happen with AD8.
Taking stock of returns so far, well 22 out of 33 stocks (excluding the last two entry last couple of days) or 67% returned double digit gains within the span of less than 6 months, some take shorter times others take longer but so far eventually they make good (fingers crossed the record holds going forwards). Stocks are selected with one major criteria - they must have already received validation (customer adoption) in their stage of progress i.e they are not concept stocks or at their infancy in business development. The largest gain to make is when they are just ramping up their progression , riding on recently gained strength from business validation.
|
Column 1 |
Column 2 |
Column 3 |
Column 4 |
Column 5 |
Column 6 |
Column 7 |
1 |
|
OPPORTUNITY STOCKS |
Date stock mentioned in Its Over thread |
Open price on date stock mentioned |
30/7/19 close |
Change% |
Potential Upside |
2 |
1 |
XRO [XERO] [closed] |
11/2/19 |
$ 46.200 |
$ 53.600 |
16.0% |
Phase 3-4 ; growth & getting in profitability |
3 |
2 |
MYE [MASTERMYNE] [closed] |
11/2/19 |
$ 0.840 |
$ 0.820 |
-2.4% |
Phase 4- growth |
4 |
3 |
CLV [CLOVER] [closed] |
11/2/19 |
$ 1.525 |
$ 2.130 |
39.7% |
Phase 4- growth |
5 |
4 |
SFC [SCHAEFFER] [closed] |
12/2/19 |
$ 14.480 |
$ 14.200 |
-1.9% |
Phase 4-growth |
6 |
5 |
YOW [YOWIE] [closed] |
19/2/19 |
$ 0.070 |
$ 0.090 |
28.6% |
Phase 3-validated; shareholder conflict |
7 |
6 |
CAT [CATAPULT] [closed] |
21/2/19 |
$ 0.640 |
$ 0.840 |
31.3% |
Phase 3-validated |
8 |
7 |
PME [PROMEDICUS] [closed] |
21/2/19 |
$ 14.45 |
$ 19.95 |
38.1% |
Phase 4-growth |
9 |
8 |
VHT [VOLPARA] |
6/3/19 |
$ 1.147 |
$ 1.640 |
43.0% |
Phase 2-3 -validating & ramping |
10 |
9 |
NST [NORTHERN STAR] |
8/3/19 |
$ 8.87 |
$ 13.41 |
51.2% |
Phase 4- defensive growth |
11 |
10 |
ANO [ADVANCED NANOTEK] [closed] |
8/3/19 |
$ 3.05 |
$ 5.00 |
63.9% |
Phase 4-growth |
12 |
11 |
CYL [CATALYST METALS] |
13/3/19 |
$ 2.30 |
$ 2.25 |
-2.2% |
Phase 1-positive discovery |
13 |
12 |
NUH [NUHEARA] [closed] |
13/3/19 |
$ 0.069 |
$ 0.061 |
-11.6% |
Phase 1-2 nearing validation; governance issue |
14 |
13 |
MWY [MIDWAY] |
14/3/19 |
$ 3.980 |
$ 3.540 |
-11.1% |
Phase 4- growth |
15 |
14 |
D20 [DUXTON WATER] |
27/3/19 |
$ 1.530 |
$ 1.370 |
-10.5% |
Phase 4-defensive growth & scalability |
16 |
15 |
PNV [POLYNOVO] |
1/4/19 |
$ 0.760 |
$ 1.615 |
112.5% |
Phase 2-3- validated & ramping & getting into profitability |
17 |
16 |
DUB [DUBBER] |
8/4/19 |
$ 0.925 |
$ 1.200 |
29.7% |
Phase 2-3- validated & ramping |
18 |
17 |
TTT [TITOMIC] |
8/4/19 |
$ 2.300 |
$ 2.000 |
-13.0% |
Phase 1-positive discovery |
19 |
18 |
EVS [ENVIROSUITE] |
10/4/19 |
$ 0.170 |
$ 0.140 |
-17.6% |
Phase 2-3- validated & ramping |
20 |
19 |
AD8 [AUDINATE] |
10/4/19 |
$ 6.290 |
$ 7.380 |
17.3% |
Phase 3- validated, ramping into profitable growth |
21 |
20 |
TNY [TINY BEANS] |
23/4/19 |
$ 0.605 |
$ 1.075 |
77.7% |
Phase 2-3- validated & ramping & getting into profitability |
22 |
21 |
MVP [MEDICAL DEV ITNL] |
26/4/19 |
$ 5.450 |
$ 5.670 |
4.0% |
Phase 3-4-growth |
23 |
22 |
STG [STRAKER TRANSLATIONS] |
29/4/19 |
$ 1.580 |
$ 2.090 |
32.3% |
Phase 2-3- validated & ramping & getting into profitability |
24 |
23 |
PPS [PRAEMIUM] |
21/5/19 |
$ 0.400 |
$ 0.535 |
33.8% |
Re-rating opportunity from an oversold position |
25 |
24 |
NXS [NEXT SCIENCE] |
22/5/19 |
$ 2.400 |
$ 2.840 |
18.3% |
Phase 2- validated & just started growth phase [significant potential] |
26 |
25 |
BLACK CAT SYND [BC8] |
22/5/19 |
$ 0.295 |
$ 0.385 |
30.5% |
Phase 1- positive discovery |
27 |
26 |
I SIGN THIS [ISX] |
27/5/19 |
$ 0.645 |
$ 0.800 |
24.0% |
Phase 2-3- validated & ramping & getting into profitability |
28 |
27 |
PROTEOMICS [PIQ] |
4/6/19 |
$ 0.275 |
$ 0.325 |
18.2% |
Phase 1- positive validated IP , awaiting business development catalyst for a substantial re-rate |
29 |
28 |
ANO [ADVANCED NANOTEK] |
12/6/19 |
$ 6.09 |
$ 5.270 |
-13.5% |
Phase 4-growth |
30 |
29 |
CLV [CLOVER] [closed] |
13/6/19 |
$ 1.875 |
$ 2.270 |
21.1% |
Phase 4- growth |
31 |
30 |
AMS [ATOMOS] |
1/7/19 |
$ 1.080 |
$ 1.385 |
28.2% |
Phase 3- growth, ebitda positive high growth high margin business |
32 |
31 |
OEC [ORBITAL CORP] |
4/7/19 |
$ 0.350 |
$ 0.330 |
-5.7% |
Undervalued $25m company that has secured a min $120m 5 year contract with Boeing subsidiary |
33 |
32 |
CHN [CHALICE GOLD MINES] |
19/7/19 |
$ 0.140 |
$ 0.170 |
21.4% |
$40M junior gold mine with impeccable record |
34 |
33 |
CAT [CATAPULT] |
23/7/19 |
$ 1.080 |
$ 1.280 |
18.5% |
Highly validated niche tech growth business- in sight of venture caps |
35 |
34 |
VGL [VISTA GROUP INTL] |
29/7/19 |
$ 5.970 |
$ 5.960 |
-0.2% |
No 1 Global Leader in Cinema Management Solution trading under $1b |
36 |
35 |
CXZ [CONNEXION TELEMATICS] |
30/7/19 |
$ 0.022 |
$ 0.022 |
0.0% |
Exclusive Software App servicing General Motors program valued at mere $20m |
37 |
|
COMPOSITE RETURN% ex Lottery Stocks |
|
|
|
20.3% |
|
38 |
|
LOTTERY STOCKS |
|
|
|
|
|
39 |
32 |
4DS [4DS] [closed] |
20/2/19 |
$ 0.067 |
$ 0.076 |
13.4% |
Phase 1-positive discovery |
40 |
33 |
BIT [BIOTRON] [closed] |
20/2/19 |
$ 0.090 |
$ 0.100 |
11.1% |
Phase 1-positive discovery |
41 |
34 |
ACW [ACTINOGEN] [closed] |
20/2/19 |
$ 0.054 |
$ 0.014 |
-74.1% |
Failed to demonstrate cognitive improvement |
42 |
35 |
LOM [LUCAPA DIAMOND] |
31/5/19 |
$ 0.150 |
$ 0.165 |
10.0% |
Undervalued and a spec punt for Lulo mother load find |
43 |
|
COMPOSITE RETURN% incl Lottery Stocks at 1/4 weighting of Core Stocks |
|
|
|
19.4% |
|
44 |
|
SMALL CAP ORDS RETURN% SINCE 11/2/19 |
|
|
|
11.5% |
|
45 |
|
SUPPLEMENTARY STOCK |
|
|
|
|
|
46 |
S-1 |
AER [AERRIS] |
2/5/19 |
$ 0.100 |
$ 0.150 |
50.0% |
Phase 2- $6m penny stock / validated |
47 |
S-2 |
LBT [LBT INNOVATIONS] |
28/6/19 |
$ 0.120 |
$ 0.120 |
0.0% |
Product FDA validated $28m market cap |
48 |
S-3 |
UUV [AQUABOTIX] |
3/7/19 |
$ 0.008 |
$ 0.006 |
-25.0% |
US Defence endorsed Swarm robotic drone IP tech for <$3m! |
49 |
|
COMPOSITE RETURN% incl Lottery Stocks+Supplementary Stocks at 1/4 weighting of Core Stocks |
|
|
|
19.2% |
|